- Home
- RDZN vs ACOG Comparison
RDZN vs ACOG Comparison
Compare RDZN & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDZN
- ACOG
- Stock Information
- Founded
- RDZN 2015
- ACOG 2000
- Country
- RDZN United States
- ACOG Canada
- Employees
- RDZN N/A
- ACOG N/A
- Industry
- RDZN Blank Checks
- ACOG
- Sector
- RDZN Finance
- ACOG
- Exchange
- RDZN Nasdaq
- ACOG Nasdaq
- Market Cap
- RDZN 86.1M
- ACOG 91.6M
- IPO Year
- RDZN N/A
- ACOG N/A
- Fundamental
- Price
- RDZN $1.11
- ACOG $4.96
- Analyst Decision
- RDZN Strong Buy
- ACOG Strong Buy
- Analyst Count
- RDZN 2
- ACOG 1
- Target Price
- RDZN $5.00
- ACOG $20.00
- AVG Volume (30 Days)
- RDZN 178.0K
- ACOG 38.8K
- Earning Date
- RDZN 02-12-2025
- ACOG 05-20-2025
- Dividend Yield
- RDZN N/A
- ACOG N/A
- EPS Growth
- RDZN N/A
- ACOG N/A
- EPS
- RDZN N/A
- ACOG N/A
- Revenue
- RDZN $42,893,256.00
- ACOG N/A
- Revenue This Year
- RDZN $4.52
- ACOG N/A
- Revenue Next Year
- RDZN $53.72
- ACOG N/A
- P/E Ratio
- RDZN N/A
- ACOG N/A
- Revenue Growth
- RDZN 2.79
- ACOG N/A
- 52 Week Low
- RDZN $0.71
- ACOG $4.66
- 52 Week High
- RDZN $6.67
- ACOG $7.00
- Technical
- Relative Strength Index (RSI)
- RDZN 48.30
- ACOG N/A
- Support Level
- RDZN $0.96
- ACOG N/A
- Resistance Level
- RDZN $1.38
- ACOG N/A
- Average True Range (ATR)
- RDZN 0.13
- ACOG 0.00
- MACD
- RDZN 0.02
- ACOG 0.00
- Stochastic Oscillator
- RDZN 32.14
- ACOG 0.00
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.